Capecitabine
Capecitabine is an antifolate anticancer chemotherapeutic that acts as a prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine carbamate that inhibits thymidylate synthase. Capecitabine is converted to 5-FU by thymidine phosphorylase in vivo. Capecitabine displays varying efficacy in the treatment of colorectal, metastatic breast, prostate, ovarian, and pancreatic cancers.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18848162
| Cas No. |
154361-50-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C15H22FN3O6 |
| Formula Wt. |
359.35 |
| Chemical Name |
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| IUPAC Name |
pentylN-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
| Melting Point |
110-121°C |
| Appearance |
White to off white powder |
Wilson PM, Fazzone W, LaBonte MJ, et al. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther. 2008 Sep;7(9):3029-37. PMID: 18790783.
Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005 Jan;27(1):23-44. PMID: 15763604.
Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998 Apr 1;55(7):1091-7. PMID: 9605432.
